JP2007503432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503432A5 JP2007503432A5 JP2006524604A JP2006524604A JP2007503432A5 JP 2007503432 A5 JP2007503432 A5 JP 2007503432A5 JP 2006524604 A JP2006524604 A JP 2006524604A JP 2006524604 A JP2006524604 A JP 2006524604A JP 2007503432 A5 JP2007503432 A5 JP 2007503432A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- formula
- compound
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- -1 2-furylmethoxy Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 125000001153 fluoro group Chemical group F* 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052717 sulfur Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 239000001301 oxygen Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 125000003302 alkenyloxy group Chemical group 0.000 claims 5
- 125000005133 alkynyloxy group Chemical group 0.000 claims 5
- 102000009410 Chemokine receptor Human genes 0.000 claims 4
- 108050000299 Chemokine receptor Proteins 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- RHWGJQJYNZZPHX-UHFFFAOYSA-N 2,3-dichloro-n-(2-methoxypyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CN=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl RHWGJQJYNZZPHX-UHFFFAOYSA-N 0.000 claims 2
- SZFIIAMMZMHZLY-UHFFFAOYSA-N 2,3-dichloro-n-(3,6,7-trimethoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC=1N=C2C=C(OC)C(OC)=CC2=NC=1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl SZFIIAMMZMHZLY-UHFFFAOYSA-N 0.000 claims 2
- WJBGUPUNKBULLR-UHFFFAOYSA-N 2,3-dichloro-n-(3-methoxypyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=NC=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl WJBGUPUNKBULLR-UHFFFAOYSA-N 0.000 claims 2
- FDQKLKSLDWVXLG-UHFFFAOYSA-N 2,3-dichloro-n-(3-methoxypyrido[3,4-b]pyrazin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CN=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl FDQKLKSLDWVXLG-UHFFFAOYSA-N 0.000 claims 2
- NHGRPSRQLPHEMF-UHFFFAOYSA-N 2,3-dichloro-n-(3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl NHGRPSRQLPHEMF-UHFFFAOYSA-N 0.000 claims 2
- OANFATXFRQSVOV-UHFFFAOYSA-N 2,3-dichloro-n-(6,7-dichloro-3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC(Cl)=C(Cl)C=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl OANFATXFRQSVOV-UHFFFAOYSA-N 0.000 claims 2
- KUALZWIOMOLXFZ-UHFFFAOYSA-N 5-chloro-n-(3-methoxyquinoxalin-2-yl)thiophene-2-sulfonamide;2,3-dichloro-n-(3,7-dimethoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(Cl)S1.N=1C2=CC(OC)=CC=C2N=C(OC)C=1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl KUALZWIOMOLXFZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- BRTQKDSZTUTDGQ-UHFFFAOYSA-N n-(3-methoxyquinoxalin-2-yl)-4-methylbenzenesulfonamide;n-(3-methoxyquinoxalin-2-yl)thiophene-2-sulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CS1.COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 BRTQKDSZTUTDGQ-UHFFFAOYSA-N 0.000 claims 2
- JPHVJWNFBPOISP-UHFFFAOYSA-N n-(7-bromo-2-methoxypyrido[2,3-b]pyrazin-3-yl)-2,3-dichlorobenzenesulfonamide Chemical compound COC1=NC2=CC(Br)=CN=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl JPHVJWNFBPOISP-UHFFFAOYSA-N 0.000 claims 2
- JXTKYWDKKKCMSZ-UHFFFAOYSA-N n-(7-bromo-3-methoxypyrido[2,3-b]pyrazin-2-yl)-2,3-dichlorobenzenesulfonamide Chemical compound COC1=NC2=NC=C(Br)C=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl JXTKYWDKKKCMSZ-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 1
- 102000004498 CCR4 Receptors Human genes 0.000 claims 1
- 108010017317 CCR4 Receptors Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- MDPCPLUKDJWCIZ-UHFFFAOYSA-N n-(3-chloroquinoxalin-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1Cl MDPCPLUKDJWCIZ-UHFFFAOYSA-N 0.000 claims 1
- NQMQRGNWHJIWHW-UHFFFAOYSA-N n-(3-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound ClC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 NQMQRGNWHJIWHW-UHFFFAOYSA-N 0.000 claims 1
- GRGHJRZOEBSNLB-UHFFFAOYSA-N n-(3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 GRGHJRZOEBSNLB-UHFFFAOYSA-N 0.000 claims 1
- NKINKNYHHBSAHN-UHFFFAOYSA-N n-[3-(furan-2-ylmethoxy)quinoxalin-2-yl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1OCC1=CC=CO1 NKINKNYHHBSAHN-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 1
- 0 *c1nc(****2)c2nc1N Chemical compound *c1nc(****2)c2nc1N 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- RVXKHAITGKBBAC-SFHVURJKSA-N n-[(1s)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine Chemical compound C([C@H](NC=1OC2=CC=C(C=C2N=1)C)C=1N=CC=CC=1)C1CCCCC1 RVXKHAITGKBBAC-SFHVURJKSA-N 0.000 description 1
- 229950010666 ontazolast Drugs 0.000 description 1
- YKGCCFHSXQHWIG-UHFFFAOYSA-N phenothiazin-3-one Chemical class C1=CC=C2SC3=CC(=O)C=CC3=NC2=C1 YKGCCFHSXQHWIG-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302304A SE0302304D0 (sv) | 2003-08-27 | 2003-08-27 | Novel compounds |
| PCT/SE2004/001227 WO2005021513A1 (en) | 2003-08-27 | 2004-08-25 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503432A JP2007503432A (ja) | 2007-02-22 |
| JP2007503432A5 true JP2007503432A5 (enExample) | 2007-08-16 |
Family
ID=28673200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524604A Pending JP2007503432A (ja) | 2003-08-27 | 2004-08-25 | 新規な縮合ｎ−ピラジニル−スルホンアミドおよびケモカイン介在疾患の処置におけるそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070093491A1 (enExample) |
| EP (1) | EP1660461B1 (enExample) |
| JP (1) | JP2007503432A (enExample) |
| AT (1) | ATE411984T1 (enExample) |
| DE (1) | DE602004017332D1 (enExample) |
| ES (1) | ES2314445T3 (enExample) |
| SE (1) | SE0302304D0 (enExample) |
| WO (1) | WO2005021513A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| EP1661889A4 (en) * | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| WO2007063935A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 芳香族化合物 |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| TW200730512A (en) * | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
| ZA200904857B (en) * | 2007-02-22 | 2010-09-29 | Merck Serono Sa | Quinoxaline compounds and use thereof |
| US7940543B2 (en) * | 2008-03-19 | 2011-05-10 | Nanya Technology Corp. | Low power synchronous memory command address scheme |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| WO2010053182A1 (ja) | 2008-11-10 | 2010-05-14 | 協和発酵キリン株式会社 | キヌレニン産生抑制剤 |
| TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
| AU2011317675A1 (en) | 2010-10-20 | 2013-05-02 | Merck Serono S.A. Geneva | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)sulfonamides |
| ES2903205T3 (es) * | 2011-11-09 | 2022-03-31 | Kyowa Kirin Co Ltd | Compuestos heterocíclicos que contienen nitrógeno |
| KR101102377B1 (ko) * | 2011-11-11 | 2012-01-05 | 주식회사 에네스코 | 터빈로터 초음파 탐상용 스캐너 |
| WO2024048615A1 (ja) * | 2022-08-30 | 2024-03-07 | 協和キリン株式会社 | キノキサリン誘導体の製造方法 |
| KR102990508B1 (ko) * | 2024-12-16 | 2026-07-13 | 주식회사 대웅제약 | 신규한 설폰아미드 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1135471B (de) * | 1960-07-30 | 1962-08-30 | Basf Ag | Verfahren zur Herstellung von 3-Chlorchinoxalinderivaten |
| BE611822A (enExample) * | 1960-12-21 | |||
| FR1495549A (enExample) * | 1966-08-08 | 1967-12-20 | ||
| CS156880B1 (enExample) * | 1972-02-09 | 1974-08-23 | ||
| EP0215200B1 (en) * | 1985-06-24 | 1992-09-09 | Merck & Co. Inc. | Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases |
| US5529999A (en) * | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| AUPN842196A0 (en) * | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| AU2002358390A1 (en) * | 2001-12-18 | 2003-06-30 | Astrazeneca Ab | Novel compounds |
| TWI328007B (en) * | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| WO2004007472A1 (ja) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
-
2003
- 2003-08-27 SE SE0302304A patent/SE0302304D0/xx unknown
-
2004
- 2004-08-25 DE DE602004017332T patent/DE602004017332D1/de not_active Expired - Fee Related
- 2004-08-25 JP JP2006524604A patent/JP2007503432A/ja active Pending
- 2004-08-25 WO PCT/SE2004/001227 patent/WO2005021513A1/en not_active Ceased
- 2004-08-25 AT AT04775333T patent/ATE411984T1/de not_active IP Right Cessation
- 2004-08-25 US US10/570,178 patent/US20070093491A1/en not_active Abandoned
- 2004-08-25 ES ES04775333T patent/ES2314445T3/es not_active Expired - Lifetime
- 2004-08-25 EP EP04775333A patent/EP1660461B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2734390C2 (ru) | Гетероциклические производные и их применение | |
| KR102477187B1 (ko) | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 | |
| JP6775516B2 (ja) | 新奇な３−インドール置換誘導体、医薬組成物、および使用方法 | |
| EP3004057B1 (en) | Heterocyclic derivatives and their use as stat 3 inhibitors | |
| RU2010154172A (ru) | Соединения для лечения рака | |
| BRPI0816994B1 (pt) | derivado uracila ou timina para tratar hepatite c | |
| JP2006524222A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
| CN111303147B (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
| WO2013049567A1 (en) | Compounds for the treatment of mycobacterial infections | |
| JP2022533958A5 (enExample) | ||
| CN1126472A (zh) | 5-ht4受体拮抗物 | |
| EP3645516A1 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
| JP2010506919A5 (enExample) | ||
| JP2020516616A5 (enExample) | ||
| JP2020511450A5 (enExample) | ||
| JP2006516626A5 (enExample) | ||
| JP2005511594A5 (enExample) | ||
| JP2006515572A5 (enExample) | ||
| ES2211608T3 (es) | Compuestos de n-arilmetiltioanilida utiles para inhibir la replicacion del vih. | |
| RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина |